Shenzhen Enduring Biotech

Shenzhen Enduring Biotech is a clinical-stage biotechnology company founded in 2018 and headquartered in Shenzhen, China. The company is dedicated to the research and development of innovative antibody therapeutics, focusing primarily on oncology and autoimmune diseases. Leveraging its proprietary Dual Site-specific PEGylated Bispecific Antibody (DSP-BsAb) and PEGylated Bispecific ADC (P-BsADC) platforms, Shenzhen Enduring Biotech designs therapies with enhanced safety, improved tumor penetration, and reduced systemic toxicities, such as cytokine release syndrome. Its lead candidate, JY108, is a long-acting PEGylated bispecific T-cell engager targeting CD3 and CD19, which has received FDA IND clearance for clinical trials in CD19-positive hematologic malignancies and autoimmune disorders. The company's pipeline also includes several preclinical bispecific antibody-drug conjugates (ADCs) targeting HER2, CD47, and PD-L1.